Studie - Overactive Bladder - Pipeline Review, H2 2011
Global Markets Direct
10 / 2011
101 Seiten
| Typ: | Studie |
| Sprache: | Englisch |
| Regionen: | Europa, Asien / Pazifik, Mittlerer Osten / Afrika, Nordamerika / USA, Australien, Mittel- / Südamerika |
| Verfügbarkeit: | verfügbar |
Bitte wählen Sie ein Lieferformat und klicken Sie unten auf einen Bestellbutton:
Overactive Bladder - Pipeline Review, H2 2011
Summary
Global Markets Direct’s, 'Overactive Bladder - Pipeline Review, H2 2011', provides an overview of the Overactive Bladder therapeutic pipeline. This report provides information on the therapeutic development for Overactive Bladder, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Overactive Bladder. 'Overactive Bladder - Pipeline Review, H2 2011' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- A snapshot of the global therapeutic scenario for Overactive Bladder.
- A review of the Overactive Bladder products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Overactive Bladder pipeline on the basis of route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.
Reasons to buy
- Identify and understand important and diverse types of therapeutics under development for Overactive Bladder.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Overactive Bladder pipeline depth and focus of Overactive Bladder therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Summary
Global Markets Direct’s, 'Overactive Bladder - Pipeline Review, H2 2011', provides an overview of the Overactive Bladder therapeutic pipeline. This report provides information on the therapeutic development for Overactive Bladder, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Overactive Bladder. 'Overactive Bladder - Pipeline Review, H2 2011' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- A snapshot of the global therapeutic scenario for Overactive Bladder.
- A review of the Overactive Bladder products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Overactive Bladder pipeline on the basis of route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.
Reasons to buy
- Identify and understand important and diverse types of therapeutics under development for Overactive Bladder.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Overactive Bladder pipeline depth and focus of Overactive Bladder therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
Table of Contents
Table of Contents 2
List of Tables 7
List of Figures 8
Introduction 9
Global Markets Direct Report Coverage 9
Overactive Bladder Overview 10
Therapeutics Development 11
An Overview of Pipeline Products for Overactive Bladder 11
Overactive Bladder Therapeutics under Development by Companies 13
Overactive Bladder Therapeutics under Investigation by Universities/Institutes 15
Late Stage Products 16
Comparative Analysis 16
Mid Clinical Stage Products 17
Comparative Analysis 17
Early Clinical Stage Products 18
Comparative Analysis 18
Discovery and Pre-Clinical Stage Products 19
Comparative Analysis 19
Overactive Bladder Therapeutics - Products under Development by Companies 20
Overactive Bladder Therapeutics - Products under Investigation by Universities/Institutes 23
Companies Involved in Overactive Bladder Therapeutics Development 24
Allergan, Inc. 24
Antares Pharma, Inc. 24
Dainippon Sumitomo Pharma Co., Ltd. 25
American Oriental Bioengineering, Inc. 25
Astellas Pharma Inc. 26
Auxilium Pharmaceuticals, Inc. 26
Japan Tobacco Inc. 27
Kissei Pharmaceutical Co., Ltd. 27
Ono Pharmaceutical Co., Ltd. 28
Pfizer Inc. 28
Recordati S.p.A. 29
Teva Pharmaceutical Industries Limited 29
Merck KGaA 30
Hisamitsu Pharmaceutical Co., Inc. 30
Urigen Pharmaceuticals, Inc. 31
Plethora Solutions Holdings plc 31
KeyNeurotek Pharmaceuticals AG 32
Respiratorius AB 32
PharmEste 33
Hydra Biosciences, Inc. 33
Mt Cook Pharma. Inc. 34
Ion Channel Innovations, LLC 34
Overactive Bladder - Therapeutics Assessment 35
Assessment by Monotherapy Products 35
Assessment by Combination Products 36
Assessment by Route of Administration 37
Assessment by Molecule Type 39
Drug Profiles 41
SMP-986 - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
ASP3652 - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
YM905 - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
Betanis - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
UK-369003 - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
AA4010 - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
Anturol - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
APT - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
REC 0422 - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
REC 1819 - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
PSD506 - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
URG302 - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
XEN-D0501 - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
JTS-653 - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
KN203 - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
MK-4618 - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
ONO-8539 - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
ONO-8539 - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
KUC-7483 - Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
Botox - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
Botox - Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
Botox - Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
MCP-202 - Drug Profile 66
Product Description 66
Mechanism of Action 66
R&D Progress 66
AGN-214868 - Drug Profile 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
MCP-101 - Drug Profile 68
Product Description 68
Mechanism of Action 68
R&D Progress 68
AOBO-001 - Drug Profile 69
Product Description 69
Mechanism of Action 69
R&D Progress 69
THVD-201 - Drug Profile 70
Product Description 70
Mechanism of Action 70
R&D Progress 70
Bryophyllum Pinnatum - Drug Profile 71
Product Description 71
Mechanism of Action 71
R&D Progress 71
DR-3001 - Drug Profile 72
Product Description 72
Mechanism of Action 72
R&D Progress 72
HC-067047 - Drug Profile 73
Product Description 73
Mechanism of Action 73
R&D Progress 73
pVAX-hSlo - Drug Profile 74
Product Description 74
Mechanism of Action 74
R&D Progress 74
REC 0436 - Drug Profile 76
Product Description 76
Mechanism of Action 76
R&D Progress 76
TRPs antagonists - Drug Profile 77
Product Description 77
Mechanism of Action 77
R&D Progress 77
Second Generation Of TRPV1 Antagonists - Drug Profile 78
Product Description 78
Mechanism of Action 78
R&D Progress 78
Liposome Encapsulated Botulinum Toxin A - Drug Profile 79
Product Description 79
Mechanism of Action 79
R&D Progress 79
Tolterodine + Tamsulosin - Drug Profile 80
Product Description 80
Mechanism of Action 80
R&D Progress 80
TD9594 - Drug Profile 81
Product Description 81
Mechanism of Action 81
R&D Progress 81
THVD-101a - Drug Profile 82
Product Description 82
Mechanism of Action 82
R&D Progress 82
THVD-202 - Drug Profile 83
Product Description 83
Mechanism of Action 83
R&D Progress 83
THVD-302 - Drug Profile 84
Product Description 84
Mechanism of Action 84
R&D Progress 84
THVD-402 - Drug Profile 85
Product Description 85
Mechanism of Action 85
R&D Progress 85
THVD-502 - Drug Profile 86
Product Description 86
Mechanism of Action 86
R&D Progress 86
Targeted Toxin - Drug Profile 87
Product Description 87
Mechanism of Action 87
R&D Progress 87
HOB-294 - Drug Profile 88
Product Description 88
Mechanism of Action 88
R&D Progress 88
Overactive Bladder Therapeutics — Drug Profile Updates 89
Overactive Bladder Therapeutics - Discontinued Products 93
Overactive Bladder - Featured News 94
Aug 29, 2011: Astellas Pharma Announces Regulatory Submissions For Mirabegron For Overactive Bladder In US And Europe 94
Jul 01, 2011: Astellas Receives Approval For Betanis Tablet In Japan For Overactive Bladder 94
May 16, 2011: TheraVida Initiates Phase II Trial Of THVD-201 For Overactive Bladder And Urinary Incontinence 95
Apr 08, 2011: Antares Announces FDA Acceptance Of Anturol NDA For Filing 95
Mar 22, 2011: TheraVida Announces Positive Results From Phase I Trial Of THVD-201 96
Mar 21, 2011: Astellas Announces Encouraging Results From Phase III Study of Mirabegron In OAB 96
Mar 02, 2011: Syntaxin's Partner Allergan Initiates Two Phase II Trials With Re-Targeted Endopeptidase Drug 97
Feb 14, 2011: Antares Pharma Announces Receipt Of NDA User Fee Waiver 97
Jan 11, 2011: FemmePharma Completes FP 1097 Phase II Clinical Trial In Overactive Bladder 98
Dec 22, 2010: Antares Pharma Files New Drug Application For Anturol For Overactive Bladder 98
Appendix 100
Methodology 100
Coverage 100
Secondary Research 100
Primary Research 100
Expert Panel Validation 101
Contact Us 101
Disclaimer 101
List of Tables
Number of Products Under Development for Overactive Bladder, H2 2011 11
Products under Development for Overactive Bladder — Comparative Analysis, H2 2011 12
Number of Products under Development by Companies, H2 2011 14
Number of Products under Investigation by Universities/Institutes, H2 2011 15
Comparative Analysis by Late Stage Development, H2 2011 16
Comparative Analysis by Mid Clinical Stage Development, H2 2011 17
Comparative Analysis by Early Clinical Stage Development, H2 2011 18
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2011 19
Products under Development by Companies, H2 2011 20
Products under Development by Companies, H2 2011 21
Products under Development by Companies, H2 2011 22
Products under Investigation by Universities/Institutes, H2 2011 23
Allergan, Inc., H2 2011 24
Antares Pharma, Inc., H2 2011 24
Dainippon Sumitomo Pharma Co., Ltd., H2 2011 25
American Oriental Bioengineering, Inc., H2 2011 25
Astellas Pharma Inc., H2 2011 26
Auxilium Pharmaceuticals, Inc., H2 2011 26
Japan Tobacco Inc., H2 2011 27
Kissei Pharmaceutical Co., Ltd., H2 2011 27
Ono Pharmaceutical Co., Ltd., H2 2011 28
Pfizer Inc., H2 2011 28
Recordati S.p.A., H2 2011 29
Teva Pharmaceutical Industries Limited, H2 2011 29
Merck KGaA, H2 2011 30
Hisamitsu Pharmaceutical Co., Inc., H2 2011 30
Urigen Pharmaceuticals, Inc., H2 2011 31
Plethora Solutions Holdings plc, H2 2011 31
KeyNeurotek Pharmaceuticals AG, H2 2011 32
Respiratorius AB, H2 2011 32
PharmEste, H2 2011 33
Hydra Biosciences, Inc., H2 2011 33
Mt Cook Pharma. Inc., H2 2011 34
Ion Channel Innovations, LLC, H2 2011 34
Assessment by Monotherapy Products, H2 2011 35
Assessment by Combination Products 36
Assessment by Stage and Route of Administration, H2 2011 38
Assessment by Molecule Type, H2 2011 40
Overactive Bladder Therapeutics — Drug Profile Updates 89
Discontinued Products 93
List of Figures
Number of Products under Development for Overactive Bladder, H2 2011 11
Products under Development for Overactive Bladder — Comparative Analysis, H2 2011 12
Products under Development by Companies, H2 2011 13
Products under Investigation by Universities/Institutes, H2 2011 15
Late Stage Products, H2 2011 16
Mid Clinical Stage Products, H2 2011 17
Early Clinical Stage Products, H2 2011 18
Discovery and Pre-Clinical Stage Products, H2 2011 19
Assessment by Monotherapy Products, H2 2011 35
Assessment by Combination Products, H2 2011 36
Assessment by Route of Administration, H2 2011 37
Assessment by Stage and Route of Administration, H2 2011 38
Assessment by Molecule Type, H2 2011 39
Assessment by Stage and Molecule Type, H2 2011 40
Table of Contents 2
List of Tables 7
List of Figures 8
Introduction 9
Global Markets Direct Report Coverage 9
Overactive Bladder Overview 10
Therapeutics Development 11
An Overview of Pipeline Products for Overactive Bladder 11
Overactive Bladder Therapeutics under Development by Companies 13
Overactive Bladder Therapeutics under Investigation by Universities/Institutes 15
Late Stage Products 16
Comparative Analysis 16
Mid Clinical Stage Products 17
Comparative Analysis 17
Early Clinical Stage Products 18
Comparative Analysis 18
Discovery and Pre-Clinical Stage Products 19
Comparative Analysis 19
Overactive Bladder Therapeutics - Products under Development by Companies 20
Overactive Bladder Therapeutics - Products under Investigation by Universities/Institutes 23
Companies Involved in Overactive Bladder Therapeutics Development 24
Allergan, Inc. 24
Antares Pharma, Inc. 24
Dainippon Sumitomo Pharma Co., Ltd. 25
American Oriental Bioengineering, Inc. 25
Astellas Pharma Inc. 26
Auxilium Pharmaceuticals, Inc. 26
Japan Tobacco Inc. 27
Kissei Pharmaceutical Co., Ltd. 27
Ono Pharmaceutical Co., Ltd. 28
Pfizer Inc. 28
Recordati S.p.A. 29
Teva Pharmaceutical Industries Limited 29
Merck KGaA 30
Hisamitsu Pharmaceutical Co., Inc. 30
Urigen Pharmaceuticals, Inc. 31
Plethora Solutions Holdings plc 31
KeyNeurotek Pharmaceuticals AG 32
Respiratorius AB 32
PharmEste 33
Hydra Biosciences, Inc. 33
Mt Cook Pharma. Inc. 34
Ion Channel Innovations, LLC 34
Overactive Bladder - Therapeutics Assessment 35
Assessment by Monotherapy Products 35
Assessment by Combination Products 36
Assessment by Route of Administration 37
Assessment by Molecule Type 39
Drug Profiles 41
SMP-986 - Drug Profile 41
Product Description 41
Mechanism of Action 41
R&D Progress 41
ASP3652 - Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
YM905 - Drug Profile 43
Product Description 43
Mechanism of Action 43
R&D Progress 43
Betanis - Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
UK-369003 - Drug Profile 45
Product Description 45
Mechanism of Action 45
R&D Progress 45
AA4010 - Drug Profile 46
Product Description 46
Mechanism of Action 46
R&D Progress 46
Anturol - Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
APT - Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
REC 0422 - Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
REC 1819 - Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
PSD506 - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
URG302 - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
XEN-D0501 - Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
JTS-653 - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
KN203 - Drug Profile 56
Product Description 56
Mechanism of Action 56
R&D Progress 56
MK-4618 - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
ONO-8539 - Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
ONO-8539 - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
KUC-7483 - Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
Botox - Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
Botox - Drug Profile 63
Product Description 63
Mechanism of Action 63
R&D Progress 63
Botox - Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
MCP-202 - Drug Profile 66
Product Description 66
Mechanism of Action 66
R&D Progress 66
AGN-214868 - Drug Profile 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
MCP-101 - Drug Profile 68
Product Description 68
Mechanism of Action 68
R&D Progress 68
AOBO-001 - Drug Profile 69
Product Description 69
Mechanism of Action 69
R&D Progress 69
THVD-201 - Drug Profile 70
Product Description 70
Mechanism of Action 70
R&D Progress 70
Bryophyllum Pinnatum - Drug Profile 71
Product Description 71
Mechanism of Action 71
R&D Progress 71
DR-3001 - Drug Profile 72
Product Description 72
Mechanism of Action 72
R&D Progress 72
HC-067047 - Drug Profile 73
Product Description 73
Mechanism of Action 73
R&D Progress 73
pVAX-hSlo - Drug Profile 74
Product Description 74
Mechanism of Action 74
R&D Progress 74
REC 0436 - Drug Profile 76
Product Description 76
Mechanism of Action 76
R&D Progress 76
TRPs antagonists - Drug Profile 77
Product Description 77
Mechanism of Action 77
R&D Progress 77
Second Generation Of TRPV1 Antagonists - Drug Profile 78
Product Description 78
Mechanism of Action 78
R&D Progress 78
Liposome Encapsulated Botulinum Toxin A - Drug Profile 79
Product Description 79
Mechanism of Action 79
R&D Progress 79
Tolterodine + Tamsulosin - Drug Profile 80
Product Description 80
Mechanism of Action 80
R&D Progress 80
TD9594 - Drug Profile 81
Product Description 81
Mechanism of Action 81
R&D Progress 81
THVD-101a - Drug Profile 82
Product Description 82
Mechanism of Action 82
R&D Progress 82
THVD-202 - Drug Profile 83
Product Description 83
Mechanism of Action 83
R&D Progress 83
THVD-302 - Drug Profile 84
Product Description 84
Mechanism of Action 84
R&D Progress 84
THVD-402 - Drug Profile 85
Product Description 85
Mechanism of Action 85
R&D Progress 85
THVD-502 - Drug Profile 86
Product Description 86
Mechanism of Action 86
R&D Progress 86
Targeted Toxin - Drug Profile 87
Product Description 87
Mechanism of Action 87
R&D Progress 87
HOB-294 - Drug Profile 88
Product Description 88
Mechanism of Action 88
R&D Progress 88
Overactive Bladder Therapeutics — Drug Profile Updates 89
Overactive Bladder Therapeutics - Discontinued Products 93
Overactive Bladder - Featured News 94
Aug 29, 2011: Astellas Pharma Announces Regulatory Submissions For Mirabegron For Overactive Bladder In US And Europe 94
Jul 01, 2011: Astellas Receives Approval For Betanis Tablet In Japan For Overactive Bladder 94
May 16, 2011: TheraVida Initiates Phase II Trial Of THVD-201 For Overactive Bladder And Urinary Incontinence 95
Apr 08, 2011: Antares Announces FDA Acceptance Of Anturol NDA For Filing 95
Mar 22, 2011: TheraVida Announces Positive Results From Phase I Trial Of THVD-201 96
Mar 21, 2011: Astellas Announces Encouraging Results From Phase III Study of Mirabegron In OAB 96
Mar 02, 2011: Syntaxin's Partner Allergan Initiates Two Phase II Trials With Re-Targeted Endopeptidase Drug 97
Feb 14, 2011: Antares Pharma Announces Receipt Of NDA User Fee Waiver 97
Jan 11, 2011: FemmePharma Completes FP 1097 Phase II Clinical Trial In Overactive Bladder 98
Dec 22, 2010: Antares Pharma Files New Drug Application For Anturol For Overactive Bladder 98
Appendix 100
Methodology 100
Coverage 100
Secondary Research 100
Primary Research 100
Expert Panel Validation 101
Contact Us 101
Disclaimer 101
List of Tables
Number of Products Under Development for Overactive Bladder, H2 2011 11
Products under Development for Overactive Bladder — Comparative Analysis, H2 2011 12
Number of Products under Development by Companies, H2 2011 14
Number of Products under Investigation by Universities/Institutes, H2 2011 15
Comparative Analysis by Late Stage Development, H2 2011 16
Comparative Analysis by Mid Clinical Stage Development, H2 2011 17
Comparative Analysis by Early Clinical Stage Development, H2 2011 18
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2011 19
Products under Development by Companies, H2 2011 20
Products under Development by Companies, H2 2011 21
Products under Development by Companies, H2 2011 22
Products under Investigation by Universities/Institutes, H2 2011 23
Allergan, Inc., H2 2011 24
Antares Pharma, Inc., H2 2011 24
Dainippon Sumitomo Pharma Co., Ltd., H2 2011 25
American Oriental Bioengineering, Inc., H2 2011 25
Astellas Pharma Inc., H2 2011 26
Auxilium Pharmaceuticals, Inc., H2 2011 26
Japan Tobacco Inc., H2 2011 27
Kissei Pharmaceutical Co., Ltd., H2 2011 27
Ono Pharmaceutical Co., Ltd., H2 2011 28
Pfizer Inc., H2 2011 28
Recordati S.p.A., H2 2011 29
Teva Pharmaceutical Industries Limited, H2 2011 29
Merck KGaA, H2 2011 30
Hisamitsu Pharmaceutical Co., Inc., H2 2011 30
Urigen Pharmaceuticals, Inc., H2 2011 31
Plethora Solutions Holdings plc, H2 2011 31
KeyNeurotek Pharmaceuticals AG, H2 2011 32
Respiratorius AB, H2 2011 32
PharmEste, H2 2011 33
Hydra Biosciences, Inc., H2 2011 33
Mt Cook Pharma. Inc., H2 2011 34
Ion Channel Innovations, LLC, H2 2011 34
Assessment by Monotherapy Products, H2 2011 35
Assessment by Combination Products 36
Assessment by Stage and Route of Administration, H2 2011 38
Assessment by Molecule Type, H2 2011 40
Overactive Bladder Therapeutics — Drug Profile Updates 89
Discontinued Products 93
List of Figures
Number of Products under Development for Overactive Bladder, H2 2011 11
Products under Development for Overactive Bladder — Comparative Analysis, H2 2011 12
Products under Development by Companies, H2 2011 13
Products under Investigation by Universities/Institutes, H2 2011 15
Late Stage Products, H2 2011 16
Mid Clinical Stage Products, H2 2011 17
Early Clinical Stage Products, H2 2011 18
Discovery and Pre-Clinical Stage Products, H2 2011 19
Assessment by Monotherapy Products, H2 2011 35
Assessment by Combination Products, H2 2011 36
Assessment by Route of Administration, H2 2011 37
Assessment by Stage and Route of Administration, H2 2011 38
Assessment by Molecule Type, H2 2011 39
Assessment by Stage and Molecule Type, H2 2011 40
- Growth Hormone Deficiency – Pipeline Review, H1 2013
- Chronic Kidney Disease (Chronic Renal Failure) – Pipeline Review, H1 2013
- Growth Disorders – Pipeline Review, H1 2013
- Kidney Fibrosis – Pipeline Review, H1 2013
- Urinary Incontinence – Pipeline Review, H1 2013
- Global Endocrinology Drugs Market 2012-2016
- Inguinal Hernia Global Clinical Trials Review, H1, 2013
- End-Stage Kidney Disease (End-Stage Renal Disease or ESRD) – Pipeline Review, H2 2012
- Microalbuminuria – Pipeline Review, H2 2012
- Nocturia – Pipeline Review, H2 2012
- Focal Segmental Glomerulosclerosis (FSGS) Global Clinical Trials Review, H2, 2012
- Hypoparathyroidism – Pipeline Review, H2 2012
- Proteinuria – Pipeline Review, H2 2012
- Thyroid Gland Disorders – Pipeline Review, H2 2012
- Acute Renal Failure (ARF) (Acute Kidney Injury) – Pipeline Review, H2 2012
- Hypothyroidism Global Clinical Trials Review, H2, 2012
- Interstitial Cystitis (Painful Bladder Syndrome) – Pipeline Review, H2 2012
- Other Genito Urinary Disorders – Pipeline Review, H2 2012
- Urinary Retention Global Clinical Trials Review, H2, 2012
- Focal Segmental Glomerulosclerosis (FSGS) – Pipeline Review, H2 2012
*Alle Preise sind netto ausgewiesen. In Abhängigkeit von Ihrer Rechnungsanschrift ist hierauf noch USt. zu entrichten (Deutschland z.Z. 19%). Unser Angebot richtet sich ausschließlich an Unternehmen, Gewerbetreibende und Freiberufler.
Hinweise: **The report can be shared by users within one office (one geographical location)
***Across Geographical locations (by the purchasing company only)
Für Sie protokollierte Studien / Marktanalysen:
zuletzt angesehene Studien:
Seite drucken
Seite empfehlen
Home | Werbung | Über marktforschung.de | AGB | Impressum | Sitemap | Suche © 2006 bis 2013 Alle Rechte bei marktforschung.de - Studie - Overactive Bladder - Pipeline Review, H2 2011 - Marktdaten / Marktanalysen bei marktforschung.de